RecruitingNot Applicable

Cardiometabolic Health Intervention Using Movement-to-Music Exercise

United States132 participantsStarted 2023-09-11

Plain-language summary

The study aims to test the benefits of a 24-week, cardio-emphasized Movement-to-Music exercise program for reversing cardiometabolic health risk factors compared to asynchronous, standard exercise programs among 132 adult wheelchair users. The targeted cardiometabolic health factors are waist circumference, triglycerides, "good" cholesterol, glucose, and blood pressure. Additionally, a 12-week follow-up phase (weeks 25-36) is included to see whether the gains are maintained.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. full-time or part-time use of a wheelchair device (manual wheelchair, power wheelchair, electric scooter) self-reported as the primary means of mobility
✓. ≥ 2 cardiometabolic risk factor(s),
✓. no contraindication to exercise as approved by a physician's medical clearance to exercise
✓. age ≥18 years
✓. able to use arms to exercise
✓. obtaining \< 90 minutes of moderate-intensity aerobic exercise per week in the last month
✓. not enrolled in a structured exercise program in the past 6 months
✓. able to converse and read in English.

Exclusion criteria

✕. medically unstable to perform home exercise as determined by their physician
✕. high-level tetraplegia and unable to use arms to exercise
✕. no internet access was determined via self-report and internet speed test.

What they're measuring

Cardiometabolic indicators - hsCRP

Timeframe: Baseline

Cardiometabolic indicators - HbA1C

Timeframe: Baseline

Cardiometabolic indicators - fasting insulin

Timeframe: Baseline

Cardiometabolic indicators - triglycerides

Timeframe: Baseline

Cardiometabolic indicators - cholesterol

Timeframe: Baseline

Cardiometabolic indicators - glucose

Timeframe: Baseline

Cardiometabolic indicators - hsCRP

Timeframe: 12 Weeks

Cardiometabolic indicators - HbA1C

Timeframe: 12 Weeks

Cardiometabolic indicators - fasting insulin

Trial details

NCT IDNCT05606432

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-30

Contact for this trial

Jereme Wilroy, PhD

(205) 934-0355 jdwilroy@uab.edu

View on ClinicalTrials.gov More Cardiometabolic Risk Factors in Adult Wheelchair Users trials

Plain-language summary

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. full-time or part-time use of a wheelchair device (manual wheelchair, power wheelchair, electric scooter) self-reported as the primary means of mobility
✓. ≥ 2 cardiometabolic risk factor(s),
✓. no contraindication to exercise as approved by a physician's medical clearance to exercise
✓. age ≥18 years
✓. able to use arms to exercise
✓. obtaining \< 90 minutes of moderate-intensity aerobic exercise per week in the last month
✓. not enrolled in a structured exercise program in the past 6 months
✓. able to converse and read in English.

Exclusion criteria

✕. medically unstable to perform home exercise as determined by their physician
✕. high-level tetraplegia and unable to use arms to exercise
✕. no internet access was determined via self-report and internet speed test.

What they're measuring

Cardiometabolic indicators - hsCRP

Timeframe: Baseline

Cardiometabolic indicators - HbA1C

Timeframe: Baseline

Cardiometabolic indicators - fasting insulin

Timeframe: Baseline

Cardiometabolic indicators - triglycerides

Timeframe: Baseline

Cardiometabolic indicators - cholesterol

Timeframe: Baseline

Cardiometabolic indicators - glucose

Timeframe: Baseline

Cardiometabolic indicators - hsCRP

Timeframe: 12 Weeks

Cardiometabolic indicators - HbA1C

Timeframe: 12 Weeks

Cardiometabolic indicators - fasting insulin